Enabling community‐based autologous adaptive immune cellular therapy manufactured at the point of care: A narrative review of global regulatory frameworks, affordability, and implementation strategy of a novel integrated facility and digital platform in the United States
R Brent Dixon, Renaud Warin, Jennifer Montague, Amy Austin, John D Powderly · 2026
Read Enabling community‐based autologous adaptive immune cellular therapy manufactured at the point of care: A narrative review of global regulatory frameworks, affordability, and implementation strategy of a novel integrated facility and digital platform in the United States by R Brent Dixon, Renaud Warin, Jennifer Montague, Amy Austin, John D Powderly (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13615423.txt.
Description
Dixon and co-authors review how patient-specific cell therapies could be made at the point of care in the United States. It is a narrative review from 2026. Such therapies use a patient's own immune cells, reshaped to fight disease. Central plants make them slowly and at high cost. The review covers global rule frameworks and cost. It also sets out a plan for a joined facility and digital platform in community settings. That plan spans regulators, manufacturing standards, and cell-tracking data systems.
Catalog record
| CREATOR | R Brent Dixon, Renaud Warin, Jennifer Montague, Amy Austin, John D Powderly |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |